ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Performance of Donor Derived Cell Free DNA (dd-cfDNA) in Diagnosing Subclinical and Clinical Acute Rejection in Kidney Transplant Recipients

T. Cober, P. West-Thielke, C. Miller, N. Grund, M. Altrich, A. Sutton, R. Sinha, M. Miller, S. Kleiboeker, J. Weems

Eurofins, Framingham, MA

Meeting: 2022 American Transplant Congress

Abstract number: 1396

Keywords: Graft function, Graft survival, Kidney, Protocol biopsy

Topic: Clinical Science » Kidney » 41 - Kidney Technical

Session Information

Session Name: Kidney Technical

Session Type: Poster Abstract

Date: Monday, June 6, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: The aim of this study was to examine the performance of Viracor TRAC donor derived cell free DNA (dd-cfDNA) in for-cause biopsies as well as protocol biopsies.

*Methods: This was a retrospective analysis of 605 dd-cfDNA samples from kidney transplant recipients. The samples came from patients with stable serum creatinine undergoing protocol biopsies (n=428) as well as unstable patients requiring for-cause biopsies (n=177). Next generation sequencing was used to determine the percentage of dd-cfDNA in recipient plasma post-transplant. Viracor TRAC (Transplant Rejection Allograft Check) dd-cfDNA assay queries > 100,000 single nucleotide polymorphisms (SNPs) to accurately quantify dd-cfDNA percentage in SOT patients.

*Results: Performance of the assay is shown in Table 1. The overall negative predictive value (NPV) and positive predictive value (PPV) were 82.56% and 52.73%, respectively, adjusted to 25% prevalence. When examining samples from for-cause biopsies the NPV and PPV were 80.41% and 46.36%, respectively. Performance from protocol biopsy samples provided a NPV of 83.42% and PPV 54.80%, respectively.

*Conclusions: This is the first large scope study examining dd-cfDNA values in both for cause and protocol biopsy samples. For renal transplantation, many publications of dd-cfDNA have validated the use in the clinical context of suspicion of allograft rejection. Data in patients with stable serum creatinine is limited. Surveillance biopsies for stable patients have logistical limitations and are not performed in most transplant centers. The strength of dd-cfDNA assays like Viracor TRAC lie in the NPV, being able to confidently rule out rejection. The test performance to rule out rejection was consistent in for-cause biopsy scenarios as well as protocol biopsies. The PPV however remains low in both contexts. Of note, performance is enhanced when looking at AMR compared to ACR. When dd-cfDNA assays are used alone, their clinical utility is limited to ruling out rejection.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Cober T, West-Thielke P, Miller C, Grund N, Altrich M, Sutton A, Sinha R, Miller M, Kleiboeker S, Weems J. Performance of Donor Derived Cell Free DNA (dd-cfDNA) in Diagnosing Subclinical and Clinical Acute Rejection in Kidney Transplant Recipients [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/performance-of-donor-derived-cell-free-dna-dd-cfdna-in-diagnosing-subclinical-and-clinical-acute-rejection-in-kidney-transplant-recipients/. Accessed May 29, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences